EP0334306B1 - Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe - Google Patents

Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe Download PDF

Info

Publication number
EP0334306B1
EP0334306B1 EP89105078A EP89105078A EP0334306B1 EP 0334306 B1 EP0334306 B1 EP 0334306B1 EP 89105078 A EP89105078 A EP 89105078A EP 89105078 A EP89105078 A EP 89105078A EP 0334306 B1 EP0334306 B1 EP 0334306B1
Authority
EP
European Patent Office
Prior art keywords
reservoir
release
use according
area
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89105078A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0334306A1 (de
Inventor
Fritz Dr. Herrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP0334306A1 publication Critical patent/EP0334306A1/de
Application granted granted Critical
Publication of EP0334306B1 publication Critical patent/EP0334306B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)

Definitions

  • the invention relates to the use of a device for delivering active ingredients to an acceptor.
  • the invention therefore relates generally to the use of devices with reservoirs with delivery surfaces for the controlled delivery of active ingredients from the reservoir to solid, liquid or gaseous acceptors, which decreases over time of use.
  • active substances are understood to mean substances which have a desired effect - be it an optical, a physical or a chemical / biological in a field of technology, medicine or biology, including pest control.
  • the delivery of active substances from the reservoir to a specific acceptor medium can, in principle, take place in two ways with regard to the time course.
  • the entire desired amount of active ingredient can be supplied in a single portion and, on the other hand, the desired total amount, divided into more or less large portions, can be delivered to the acceptor medium discontinuously or continuously over a certain period of time.
  • the present invention is concerned with the latter case.
  • controllability of the active substance release characteristic is also required here. This requirement is indispensable in many cases and plays an important role in the so-called transdermal therapeutic systems, for example.
  • US Pat. No. 4,564,364 proposes to subdivide the active substance reservoir into volume ranges in which the active substance concentration is set partly below and partly above the saturation concentration.
  • the geometrical design of the volume areas can be used to influence the drug delivery characteristics.
  • the teaching of technical action given here does not provide a solution to the problem of a targeted, controlled decrease in the release of active substance over the application time of the system.
  • EP-A 0 227 252 proposes reservoirs whose kinetics are determined solely by the diffusion rate of the active ingredient or the exhaustion kinetics of the active ingredient in the matrix material.
  • transdermal device for delivering VERAPAMIL has become known, by means of which the VERAPAMIL is delivered to the skin through a permeable matrix made of silicone elastomer. This device realizes a uniform dispensing speed.
  • the solution to the problem has now been found in that by using a device for delivering active ingredients to an acceptor for the controlled decrease in the number of active ingredients over the time of use with at least one drug reservoir with a delivery surface that is in contact with the acceptor, whereby at least one cross-sectional area of the reservoir parallel to the dispensing area is smaller than the dispensing area and no cross-sectional area of the reservoir parallel to the dispensing area is larger than the dispensing area and the dispensing characteristics are determined by the geometric shape of the reservoir, now a defined, controlled decrease in the active ingredient dispensing over time is ensured .
  • the amount of substance dispensed over time from a reservoir through the dispenser surface is directly proportional to the size of this dispenser surface.
  • the reservoir itself can consist of pure active substance or of a reservoir mass which remains unchanged over the period of use and in which the active substance is distributed.
  • the release of active ingredient leads to a removal of the reservoir Training more and more delivery areas. If the cross-section of the reservoir is reduced parallel to the delivery surface at at least one point, a reduced delivery surface is formed there, so that there is a decrease in the active ingredient delivery.
  • a kind of separating surface is formed parallel to the dispensing surface between the reservoir parts with reduced concentration and higher original concentration, the distance to the dispensing surface constantly increasing during application and the size of which corresponds to that of the cross section of the reservoir parallel to the dispensing surface.
  • the size of this separation area and thus the cross section of the reservoir determines the rate of release of active ingredient through the delivery area.
  • the size of the separating surface is now defined and specifically reduced by a corresponding geometric configuration of the reservoir, so that the amount of active substance released from the reservoir can be defined and reduced in a controlled manner compared to the initial amount.
  • the cross-sectional reduction can be continuous over the entire reservoir, it being possible to differentiate between a linear or non-linear course of the reduction.
  • a discontinuous, e.g. step-like cross-sectional reduction can be implemented if necessary.
  • the course can be linear or non-linear.
  • the reservoir can also be designed in such a way that the cross-sectional reduction is only formed in part of the reservoir.
  • Symmetry elements in the reservoir are not indispensable requirements for the invention Problem solving.
  • the dispensing area can have a maximum extent in one direction, which is up to 100 times the extent in the direction perpendicular thereto. In the special case of a rectangular delivery surface, this would correspond to a length that is 100 times larger than width.
  • the reservoir can also be at least partially embedded in a corresponding recess in a carrier material, it being possible for it to be fixed in the recess with at least one surface, with the exception of the dispensing surface.
  • the delivery area is preferably protected by an at least single-layer, removable and impermeable fabric for the components of the reservoir.
  • At least one such reservoir can be part of a device used according to the invention for controlled release of active substances over time of use.
  • the use of the combination of several reservoirs in such a device can be preferred, which can also differ from one another in their geometric configuration.
  • the devices preferably comprise elements which enable the device to be fixed at the application site. Adhesive areas of the device have proven particularly useful for this purpose.
  • the reservoir comprises at least one active ingredient which can be delivered to solid, liquid or gaseous acceptor media, the active ingredient (s) preferably developing its effect in the fields of technology, human and veterinary medicine, cosmetics and pest control ( n). Active substances for human medicine are preferred in devices which can be referred to as transdermal therapeutic systems.
  • the reservoir is preferably formed in an appropriate form.
  • the processes used for this purpose are preferably cooling of a melt of the reservoir mass, evaporation of solvent or dispersant, cold or hot pressing of the reservoir mass and profile extrusion or also the crosslinking of polymers by radiation or Warmth.
  • the casing of the reservoir outside the delivery surface can then preferably be done by lamination, spraying and dipping.
  • the devices for use according to the invention are preferably used in technology, human and veterinary medicine, cosmetics and pest control.
  • a particularly preferred use of the devices according to the invention is as a transdermal therapeutic system.
  • the present invention offers extensive possibilities in all cases where an active ingredient is to be released from a reservoir to any acceptor medium in such a way that a targeted and controlled decrease in the rate of release is achieved over the application time.
  • the contact of the reservoir with the acceptor medium takes place via the delivery surface.
  • This dispensing surface is part of the surface of the three-dimensional reservoir.
  • the acceptor medium is a solid substance
  • the delivery surface must be adapted to the contours of the contact surface of the solid substance so that a controllable transition of the active substance is ensured. From a manufacturing perspective, planar delivery surfaces are preferred. In the case of liquid and gaseous acceptor media, the design of the delivery surface is primarily determined by the production possibilities, since these acceptor media adapt to every form of the delivery surface.
  • the device used according to the invention comprises at least one of the described reservoirs.
  • devices with multiple reservoirs are also useful. So it may be that with a certain required delivery characteristic and delivery quantity, the size of the reservoir required for this becomes too bulky.
  • the dispensing surface is therefore broken down into sub-areas, which in turn form the dispensing surfaces of several smaller reservoirs. These can be combined in one device.
  • the possibilities The geometrical arrangement of these small reservoirs with respect to one another is not restricted by the desired delivery characteristics of the active ingredients.
  • reservoirs are indicated in one device when it comes to applying two mutually incompatible active substances at the same time according to the same or also different delivery characteristics, i.e. reservoirs of different geometrical configurations can also be combined with one another.
  • DE-U 87 09 810.5 describes a medical plaster that has geometrically defined troughs in the carrier material, which are coated with reservoir mass, such as e.g. Ointment to be filled.
  • the geometrically defined design of the troughs is intended to define the volume of the reservoir mass used for the application as precisely as possible than was possible with the devices previously used.
  • a controlled, defined delivery characteristic with regard to the decrease in the active ingredient delivery over the application time cannot be recognized in this publication.
  • the dispensing characteristic can also be influenced by defining freely selectable structural elements of the basic shape.
  • the delivery characteristics of a conical reservoir depend on the freely selectable angle in the cone tip. At small angles, a relatively high cone results that has a fairly flat decrease in drug delivery, while at large angles, a lower cone results with a steep drop in drug delivery rate. This documents how diverse the possible variations in the reservoir design for use according to the invention are.
  • the delivery rate ie the delivery amount of the active ingredient per unit of time, is determined by other factors.
  • the release rate is primarily influenced by the solubility of the active substance or the active substance preparation in the acceptor medium.
  • the second factor is of course the size of the dispensing area, which also plays an important role in the reservoirs that are constant in volume over the application time.
  • the solubility of the active ingredient in the reservoir matrix as further parameters, the concentration of the active substance in the matrix, the concentration distribution in the matrix and the diffusibility of the active substance in the matrix.
  • the temperature during drug delivery must be mentioned, which in the given case makes it advisable to cool or to warm the reservoir.
  • the reservoir becomes a dispensing device when all areas not intended for dispensing have no direct contact with the acceptor medium. They can be covered by fabrics which are impermeable both to the constituents of the reservoir and to the acceptor medium.
  • the device can optionally be fixed at the location of the application. External aids can be used for this, or the device itself is provided with fixing elements. In the latter case, pressure-sensitive adhesive areas are preferably provided.
  • the reservoir itself and thus the dispensing surface can be pressure-sensitive adhesive, or the dispensing surface is equipped with pressure-sensitive adhesive areas which allow the active substances to pass freely.
  • the pressure-sensitive areas can also be provided on other surfaces of the device if the acceptor media are liquid or gaseous.
  • the dispensing surface must be protected from the application of the device, which is preferably accomplished by a fabric that is impermeable to the components of the reservoir and can be removed again before application.
  • the substances that can be used to manufacture the device depend on their requirements in the given case and are known to the person skilled in the art.
  • the active substances which can be applied with the device are also so diverse and likewise known to the person skilled in the art that an exhaustive list is not possible.
  • the triangular longitudinal section 10 in FIG. 1 of a reservoir shows at 11 the section through the delivery surface.
  • the associated reservoir can have a cone or pyramid shape, for example.
  • 10 can be a section through the reservoir shape 40 in FIG. 4 or through the shape in FIG. 4a.
  • the cross-sectional reduction is continuously linear here.
  • the desired delivery characteristic can be set by the choice of the angle 12. 2 shows the longitudinal section 20 of a hemispherical reservoir with the dispensing surface 21, the only variable geometrical parameter being the ball diameter.
  • 20 also shows a section through the shape 50 of FIGS. 5 and 5a.
  • the longitudinal section 30 in FIG. 3 belongs to reservoirs in the form of a truncated pyramid.
  • the delivery area is designated 31.
  • the possible variations are the height of the stump and the size of the angle in the top of the associated pyramid.
  • the cross-sectional reduction must be described as continuously non-linear.
  • FIG. 4 shows the perspective view 40 of a reservoir in the form of a tent with 41 as a dispensing surface.
  • the possibility of varying the length of the upper edge 42, as shown by way of example on the reservoir of FIG. 4a, and the angle 43 determine the possible modifications of this reservoir shape.
  • the cross-sectional reduction is continuously linear here.
  • the modification of the reservoir shape 50 which is shown in perspective in FIG. 5, can only take place by varying the dispensing surface 51 and the length of the apex line 52. An example is given in Fig. 5a for the latter case.
  • the reduction of the cross-section is continuously non-linear in these cases.
  • the design of a reservoir with discontinuous cross-sectional reduction can be seen from the longitudinal section 60 in FIG. 6.
  • the reduction is linear if the reservoir has the same longitudinal section at all points.
  • the dispensing surface of the reservoir of FIG. 6 is designated by 61.
  • the geometry of the first part of the reservoir above enables a largely constant release of active ingredient. After a sudden reduction in the cross section, the cross section in the second part of the reservoir is continuously reduced.
  • FIG. 7 also shows a perspective image 70 of a reservoir with discontinuous cross-sectional reduction, the cross-section remaining constant in the individual segments. This gives you the option of gradually controlling the decrease in drug delivery. Analog reservoir structures based on many other geometric shapes are of course possible.
  • the longitudinal section through a reservoir 80 in FIG. 8 shows the combination of a truncated cone, which forms the delivery surface 81, with a hemisphere.
  • the reduction in cross-section is discontinuous and not linear in the individual parts.
  • the longitudinal section through a device according to the invention for controlling the delivery of active substance is designated by 90 in FIG. 9.
  • the reservoir 92 corresponds to the reservoir shape 10 shown in FIG. 1 and is provided with an impermeable layer 93 on the areas not intended to release the active ingredient.
  • the dispensing surface 91 is covered by a protective layer 94.
  • a pressure-sensitive adhesive layer can optionally also be arranged between the two.
  • the reservoir 102 according to FIG. 2 is embedded in the depression in a carrier material 103. If necessary, the reservoir can be fixed in the recess by an adhesive layer. Layer 104 protects the dispensing surface 101 of the reservoir 102 from use.
  • FIG. 11 can give an exemplary picture thereof. It shows a longitudinal section of a device 110, in which a plurality of conical reservoirs 112 are embedded in corresponding recesses in a carrier material 113.
  • the Dispensing surfaces 111 of the reservoir 112 adjoin a protective layer 114.
  • the geometrical arrangement of the reservoirs in relation to one another is very varied and depends on the requirements of practice.
  • FIG. 12 gives an example of the combination of two reservoirs in one device, the longitudinal section of a device 120 being shown.
  • the reservoirs 122 are in turn embedded in a carrier material 123.
  • the central reservoir 122 has no cross-sectional reductions and contains a first active ingredient which is released according to the known release characteristic.
  • a second active ingredient is incorporated in the second reservoir 122 ', which surrounds the first reservoir 122 in a ring shape and has a triangular longitudinal section, and is released in a controlled, decreasing manner.
  • 13 shows the cross section along the line I / I of the device 120.
  • the arrangement of the reservoirs 122, 122 'in the carrier material 123 can be clearly seen, the central cylindrical reservoir 122 of the first active substance being surrounded in a ring shape by the reservoir 122' of the second active substance.
  • the release of PEG-6OOO in water is determined according to the "paddle-over-disc" method according to USP XX.
  • the test specimen is removed from the bath every 30 minutes and weighed out after careful drying.
  • Paddle-over-disc device SOTAX AT 6 (Sotax AG, Basel) Release medium: 1OOO ml demineralized water Temperature: 35 degrees Celsius Stirring speed: 50 rpm Stirring height above test specimen: 15 mm
  • the release rate (flux) from a cylindrical test specimen remains constant at about 1.8 g / h for about 4 hours and then quickly drops to zero.
  • a constant release rate of about 1.8 g / h is first observed until about 2 hours after the start of the test, then a steep drop in the release rate to a release rate of 0.3 g / h takes place corresponding to the stage , which remains constant for about an hour and then drops to zero after the second stage has been used up.
  • the release rate measured as flux in g / h, drops uniformly from about 1.8 g / h at the start of the test to zero within four hours, with the decrease taking place continuously, or the decrease curve of the flux, plotted against the test time , is essentially a straight line.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Lubricants (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Catching Or Destruction (AREA)
  • Steroid Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Seasonings (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Detergent Compositions (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Nozzles (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
EP89105078A 1988-03-24 1989-03-21 Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe Expired - Lifetime EP0334306B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3809978A DE3809978A1 (de) 1988-03-24 1988-03-24 Reservoir fuer gesteuerte wirkstoffabgabe, dieses enthaltende vorrichtung, sowie verfahren zu deren herstellung und verwendung der vorrichtung
DE3809978 1988-03-24

Publications (2)

Publication Number Publication Date
EP0334306A1 EP0334306A1 (de) 1989-09-27
EP0334306B1 true EP0334306B1 (de) 1996-09-11

Family

ID=6350601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89105078A Expired - Lifetime EP0334306B1 (de) 1988-03-24 1989-03-21 Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe

Country Status (25)

Country Link
US (1) US6207181B1 (fi)
EP (1) EP0334306B1 (fi)
JP (1) JP3154478B2 (fi)
KR (1) KR0145310B1 (fi)
AT (1) ATE142517T1 (fi)
AU (1) AU639664B2 (fi)
CA (1) CA1336665C (fi)
CZ (1) CZ281559B6 (fi)
DD (1) DD283567A5 (fi)
DE (2) DE3809978A1 (fi)
ES (1) ES2103702T3 (fi)
FI (1) FI104151B (fi)
GR (1) GR3021589T3 (fi)
HU (1) HU210618B (fi)
IE (1) IE80803B1 (fi)
IL (1) IL89603A (fi)
MY (1) MY110263A (fi)
NO (1) NO174536C (fi)
NZ (1) NZ228455A (fi)
PL (1) PL162187B1 (fi)
PT (1) PT90058B (fi)
SK (1) SK279081B6 (fi)
WO (1) WO1989009080A1 (fi)
YU (1) YU60089A (fi)
ZA (1) ZA891949B (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3908432A1 (de) * 1989-03-14 1990-09-27 Lohmann Therapie Syst Lts Pflaster als therapeutisches system zur verabreichung von wirkstoffen an die haut mit einer abgestuften wirkstoffabgabe, verfahren zu seiner herstellung sowie verwendung
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
US6002797A (en) 1994-06-22 1999-12-14 Hitachi, Ltd. Apparatus for detecting position of featuring region of picture, such as subtitle or imageless part
DE19820999A1 (de) * 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
DE19923427A1 (de) 1999-05-21 2000-11-23 Lohmann Therapie Syst Lts Vorrichtung und Verfahren zur Steigerung der transdermalen Permeation von Arzneistoffen
CA2404112A1 (en) * 2000-03-21 2001-09-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
SE0101154D0 (sv) * 2001-03-29 2001-03-29 St Jude Medical An electrically conductive lead and a method of producing such a lead
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
DE10250848A1 (de) * 2002-10-24 2004-05-13 Paul Hartmann Ag Wundkontaktmaterial
EP2018835B1 (de) * 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
WO2020026061A1 (en) * 2018-07-30 2020-02-06 3M Innovative Properties Company Antimicrobial foam articles and method of making the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa

Also Published As

Publication number Publication date
NO174536C (no) 1994-05-25
PL278443A1 (en) 1989-11-27
DE3809978A1 (de) 1989-10-05
ATE142517T1 (de) 1996-09-15
NO174536B (no) 1994-02-14
IL89603A0 (en) 1989-09-10
FI104151B1 (fi) 1999-11-30
HUT53815A (en) 1990-12-28
CS8901812A2 (en) 1991-11-12
CA1336665C (en) 1995-08-15
PT90058B (pt) 1994-03-31
NO894467D0 (no) 1989-11-09
NZ228455A (en) 1990-08-28
AU3217389A (en) 1989-10-16
IE80803B1 (en) 1999-03-10
GR3021589T3 (en) 1997-02-28
JP3154478B2 (ja) 2001-04-09
SK279081B6 (sk) 1998-06-03
KR900700154A (ko) 1990-08-11
JPH02503524A (ja) 1990-10-25
PL162187B1 (en) 1993-09-30
HU210618B (en) 1995-06-28
ZA891949B (en) 1989-11-29
FI104151B (fi) 1999-11-30
DD283567A5 (de) 1990-10-17
NO894467L (no) 1989-11-09
MY110263A (en) 1998-03-31
DE3809978C2 (fi) 1992-03-12
DE58909724D1 (de) 1996-10-17
YU60089A (en) 1990-06-30
HU892315D0 (en) 1990-11-28
IE890908L (en) 1989-09-24
WO1989009080A1 (en) 1989-10-05
PT90058A (pt) 1989-11-10
FI895638A0 (fi) 1989-11-24
KR0145310B1 (ko) 1998-07-01
IL89603A (en) 1993-01-31
EP0334306A1 (de) 1989-09-27
AU639664B2 (en) 1993-08-05
ES2103702T3 (es) 1997-10-01
CZ281559B6 (cs) 1996-11-13
US6207181B1 (en) 2001-03-27

Similar Documents

Publication Publication Date Title
DE1948019C3 (de) Verfahren zur Herstellung von geformten Arzneizubereitungen mit Depotwirkung
EP0334306B1 (de) Verwendung einer Vorrichtung mit einem Wirkstoffreservoir für gesteuerte Wirkstoffabgabe
DE4341442C2 (de) Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
EP0387694B1 (de) Pflaster als therapeutisches System zur Verabreichung von Wirkstoffen an die Haut mit einer abgestuften Wirkstoffabgabe, Verfahren zu seiner Herstellung sowie Verwendung
DE202004003389U1 (de) Applicator zum Einbringen von Wirkstoffen in menschliche Haut
WO1988001516A1 (en) Transdermal therapeutic system, its use and production process
WO2006040119A2 (de) Arzeimittel und system zur perkutanen arzneistoffverabreichung
EP2265264A1 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff hiervon
DE19608423A1 (de) Implantate mit phasenweiser Arzneistoffabgabe
DE10203629A1 (de) Vorrichtung und Verfahren zur Herstellung von Mikrokapseln sowie verbesserte Mikrokapsel
DE3729299A1 (de) Transdermales therapeutisches system
DE2054488C2 (de) Vorrichtung zur Abgabe von Kontrazeptiva an den Uterus
DE4314976C1 (de) Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0387693B1 (de) Transdermales System mit gestufter Wirkstoffabgabe und Verwendung für die lokale oder systemische, kosmetische Wirkstoffverabreichung
WO1996008251A1 (de) Scopolaminpflaster
WO1988009185A1 (en) Transdermal therapeutically effective pharmaceutical dressing and device for applying it
DE3319469C2 (fi)
WO1999011265A1 (de) Transdermales therapeutisches system mit dem wirkstoff scopolaminbase
EP3359102B1 (de) Medizinisches pflaster
WO2001026636A1 (de) Superfizielles therapeutisches system zur topischen applikation von acetylsalicylsäure zur behandlung von akne-erkrankungen
EP1079815B1 (de) Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DD279818A1 (de) Verfahren zur herstellung eines medizinischen pflasters
DE202020107505U1 (de) Verbessertes Pflaster
DE102020134781A1 (de) Verbessertes Pflaster
DE3918801A1 (de) Praeparat zur geregelten wirkstoffabgabe und verfahren zu dessen herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910423

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LTS LOHMANN THERAPIE-SYSTEME GMBH

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 142517

Country of ref document: AT

Date of ref document: 19960915

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19960912

REF Corresponds to:

Ref document number: 58909724

Country of ref document: DE

Date of ref document: 19961017

ITF It: translation for a ep patent filed

Owner name: STUDIO TORTA SOCIETA' SEMPLICE

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3021589

REG Reference to a national code

Ref country code: ES

Ref legal event code: FA2A

Effective date: 19970218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2103702

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010219

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20010223

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20010226

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010228

Year of fee payment: 13

Ref country code: GR

Payment date: 20010228

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20010305

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010309

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20010313

Year of fee payment: 13

Ref country code: DE

Payment date: 20010313

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20010316

Year of fee payment: 13

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20020222

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020321

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020322

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020331

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020331

BERE Be: lapsed

Owner name: LOHMANN THERAPIE-SYSTEME G.M.B.H. *LTS

Effective date: 20020331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021001

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021007

EUG Se: european patent has lapsed

Ref document number: 89105078.3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021129

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20021001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030321

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20030321

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050321